who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Daniel Powell of Spark Biomedical, Carrie Colbert of Curate Capital, and Carson Hager of SafeFun. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — venture capital, medical devices, and software — recently making headlines in Houston innovation.

Daniel Powell, CEO of Spark Biomedical

A new medical device created in Houston is revolutionizing opioid withdrawal treatment. Photo via sparkbiomedical.com

Houston-based Spark Biomedical has created an opioid withdrawal treatment device known as the Sparrow Therapy System. It's worn over the ear and sends mild electrical signals to trigger cranial nerves that release endorphins that the body has stopped producing on its own during opioid use. These endorphins help the user to make clearer, more logical decisions as they come off of the drug.

"If you ask 100 people who've gone through opioid withdrawal, I would bet 99 of them will tell you they thought they were going to die," Spark BioMed CEO Daniel Powell says. "Giving them the ability to manage that is huge. It's the first step towards addiction recovery. It's not solving the addiction, but it is an absolute barrier to move forward."

Carrie Colbert, general partner at Curate Capital

Carrie Colbert saw an opportunity is funding female-founded companies, and she's taking it. Photo courtesy of Curate Capital

Carrie Colbert has gone from energy executive to fashion and lifestyle content creation to her latest venture — venture investment. With her multifaceted career, she's grown her network across industries and platforms and now some of her followers have become Curate Capital's limited partners.

"Instagram turned out to be one of the best networking tools for me," Colbert says. "You can connect with people wherever they are and wherever you are." Read more.

Carson Hager, president at SafeFun

A Houston entrepreneur created a free smartphone app to easily track and share COVID-19 testing results. Photo courtesy of SafeFun

Last year, Carson Hager felt helpless as he saw Houston restaurants and bars being shut down amid the COVID-19 pandemic.

"I was thinking what's it going to take for people to be able to feel comfortable to go back out again and go out to bars and restaurants, gyms, salons, club, etcetera," he says.

In April 2020, he decided to act. And with the help of a few programmer friends pulling long hours for about 100 days straight, Hager created SafeFun, a Houston-based digital health passport that allows users to voluntarily and easily share COVID-19 test results and information. Read more.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News